Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Rectal Adenocarcinoma: early-phase trial registry
12 of 18 indexed Rectal Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 12 currently recruiting · #953 of 28,707 conditions by registered trial count
Rectal Adenocarcinoma: 18 US clinical trials tracked, 12 recruiting.
Rectal Adenocarcinoma is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition rectal-adenocarcinoma
OPEN 12 | RECR 67% | LATE 2 | EARLY 13 | RANK #953 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Rectal Adenocarcinoma lists 12 open slots (67% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Rectal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Rectal Adenocarcinoma is recruiting above its size-band peers.
12 of 18 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Rectal Adenocarcinoma research.
M.D. Anderson Cancer Center accounts for 3 of 18 trials (16.7%). 13 distinct sponsors appear on at least one study for this condition label.
-
Most Rectal Adenocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 18 trials that report a genuine target (sentinel values excluded). 14 of those (77.8%) plan for fewer than 100 participants.
-
Rectal Adenocarcinoma research is mostly interventional.
15 interventional and 3 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Merck Sharp & Dohme
NCT06997497
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT04165772
Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
M.D. Anderson Cancer Center
NCT03594630
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
M.D. Anderson Cancer Center
NCT06569368
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
OHSU Knight Cancer Institute
NCT05081024
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
University of Colorado, Denver
NCT07292298
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
Institut Paoli-Calmettes
NCT03961776
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
NCT05672524
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
City of Hope Medical Center
NCT06780787
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Jonsson Comprehensive Cancer Center
NCT04703101
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
Medical College of Wisconsin
NCT04808323
Evaluating Novel Therapies in ctDNA Positive GI Cancers
Georgetown University
NCT05482516
Young-Onset Colorectal Cancer
M.D. Anderson Cancer Center
NCT02863107
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Providence Health & Services
NCT02688712
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
University of Colorado, Denver
NCT04963283
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05108428
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
OHSU Knight Cancer Institute
NCT04104139
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
Roswell Park Cancer Institute
NCT02393755
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 7 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Rectal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Rectal Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Rectal Adenocarcinoma page
18 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Rectal Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Rectal Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Rectal Adenocarcinoma condition card totals 18 registered trials; most-linked intervention Capecitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.